INTERIM REPORT
Period from January 2018 to March 2018 Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED)2018 FIRST QUARTER (Jan-Mar) · Operating loss KSEK -2,756 (-2,681) · Loss per share SEK -0.06 (-0.13) IMPORTANT EVENTS DURING THE PERIOD · On March 22nd the Company informed that it is close to CE mark for VagiVital®. This after the Company has received the report of the evaluation of its so called Technical File. The evaluation has been performed by Lloyd’s Register Quality Assurance, Ltd. (LRQA) in England, acting as the Notified Body.The Company